A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

Stopped New data suggests that insufficient target engagement would be achieved for efficacy.

Conditions

• Healthy
• Alzheimer's Disease
• Mild Cognitive Impairment

Interventions

• DRUG: LY2599666
• DRUG: Solanezumab
• DRUG: Placebo SC
• DRUG: Placebo IV

Sponsor

Eli Lilly and Company